Fig. 1.

Change from baseline in mTSS in the (A) LE and (B) as-observed analyses over 1 year

In SELECT-COMPARE, at week 26 (6-month visit), patients receiving placebo were switched to upadacitinib. The month 6 analysis was conducted at week 24 in SELECT-EARLY and week 26 in SELECT-COMPARE; the year 1 analysis was conducted at week 48 in both studies. eow, every other week; PBO, placebo; UPA, upadacitinib. ***P < 0.001 upadacitinib vs MTX or placebo. ^###P < 0.001 and ^#P < 0.05 adalimumab vs placebo.